ID   NZOV2
AC   CVCL_D812
SY   NZOV-2; New Zealand OVarian line 2
DR   cancercelllines; CVCL_D812
DR   Wikidata; Q54931648
RX   PubMed=19493612;
RX   PubMed=21912889;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr220Asp (c.658T>G); ClinVar=VCV000376689; Zygosity=Unspecified (PubMed=21912889).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7550; Ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 12
//
RX   PubMed=19493612; DOI=10.1016/j.canlet.2009.05.010;
RA   Ramachandran A., Marshall E.S., Love D.R., Baguley B.C.,
RA   Shelling A.N.;
RT   "Activin is a potent growth suppressor of epithelial ovarian cancer
RT   cells.";
RL   Cancer Lett. 285:157-165(2009).
//
RX   PubMed=21912889; DOI=10.1007/s10637-011-9744-z;
RA   Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A.,
RA   Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P.,
RA   Ding A., Baguley B.C.;
RT   "Therapeutic reactivation of mutant p53 protein by quinazoline
RT   derivatives.";
RL   Invest. New Drugs 30:2035-2045(2012).
//